Organization

Westlake Therapeutics

1 clinical trial

Clinical trial

A Multicenter, Single-arm, Open-label, Dose-escalation and Dose-expansion Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell WTX212 in Patients With Advanced Malignancies

Status: Recruiting, Estimated PCD: 2023-12-31